MMP9 and cancer: Furthermore, the downregulation of the intrinsically higher levels of MMP2 and MMP9 by COL1 in resistant W1CR cells confirm the discrete regulation of both resistance pathways and offer interesting new targets for clinical sensitization strategies in the treatment of cancer patients.